Buspirone    (DrugBank: Buspirone)

2 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease4
51Scleroderma1

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-003415-19-ES
(EUCTR)
31/10/201820/08/2018A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable.A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010 Parkinson’s Disease Patients With Moderate to Severe Dyskinesia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: JM-010
Product Code: JM-010
INN or Proposed INN: Buspirone hydrochloride
INN or Proposed INN: Zolmitriptan
Product Name: JM-010
Product Code: JM-010
INN or Proposed INN: Buspirone hydrochloride
INN or Proposed INN: Zolmitriptan
Contera PharmaNULLNot RecruitingFemale: yes
Male: yes
81Phase 2France;Spain;Germany
2NCT02803749
(ClinicalTrials.gov)
October 201614/6/2016Buspirone in Parkinson's DiseaseThe Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's DiseaseParkinson Disease;AnxietyDrug: Buspirone;Drug: PlaceboUniversity of RochesterMichael J. Fox Foundation for Parkinson's ResearchCompleted18 YearsN/AAll21Phase 2United States
3NCT02589340
(ClinicalTrials.gov)
January 201623/10/2015Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced DyskinesiaBuspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced DyskinesiaParkinson's Disease;Dyskinesias;Movement DisordersDrug: Buspirone;Drug: PlaceboOregon Health and Science UniversityPortland VA Medical CenterActive, not recruiting18 Years99 YearsAll15Phase 1United States
4EUCTR2014-005422-35-GB
(EUCTR)
28/05/201502/04/2015The role of Buspirone in attenuating involuntary movements (Dyskinesias) in patients with Parkinson's disease. THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO. - The role of buspirone in LIDs in patients with Parkinson’s disease. Levodopa induced dyskinesias within Parkinson's disease.
MedDRA version: 17.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Imperial College London-Imperial College Healthcare NHS TrustNULLNot Recruiting Female: yes
Male: yes
24Phase 4United Kingdom

51. Scleroderma    [ 466 clinical trials,   536 drugs,   (DrugBank: 142 drugs),   110 drug target genes,   210 drug target pathways]
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 466 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02363478
(ClinicalTrials.gov)
December 201429/1/2015Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)Systemic SclerosisDrug: buspironeLaikon General District Hospital, AthensNULLCompleted18 Years75 YearsAll22Early Phase 1Greece